Jazz Pharmaceuticals (JAZZ) Total Debt (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Total Debt of $5.4 billion for Q1 2026, down 0.81% year-over-year from $5.4 billion in Q1 2025, and down 16.18% quarter-over-quarter from $6.4 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Total Debt (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Total Debt history runs 17 years deep, the most recent figure standing at $5.4 billion for Q1 2026.
- In Q1 2026, Total Debt fell 0.81% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at $5.4 billion (down 0.81% YoY), while the FY2025 annual figure was $6.4 billion, up 4.58% from the prior year.
- Total Debt for Q1 2026 stood at $5.4 billion, down from $6.4 billion in the prior quarter.
- The five-year high for Total Debt was $6.4 billion in Q2 2025, with the low at $5.4 billion in Q1 2026.
- The 5-year median for Total Debt is $5.8 billion (2022), against an average of $5.9 billion.
- Peak annual rise in Total Debt reached 186.63% in 2022, while the deepest fall reached 13.38% in 2022.
- Jazz Pharmaceuticals' Total Debt stood at $5.7 billion in 2022, then dropped by 0.2% to $5.7 billion in 2023, then gained by 6.93% to $6.1 billion in 2024, then grew by 4.58% to $6.4 billion in 2025, then declined by 16.18% to $5.4 billion in 2026.
- Business Quant data shows JAZZ's Total Debt at $5.4 billion in Q1 2026, $6.4 billion in Q4 2025, and $6.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 5.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.37 Bn |
| Mar 31, 2026 | 5.35 Bn |
| Dec 31, 2025 | 6.39 Bn |
| Sep 30, 2025 | 6.39 Bn |
| Jun 30, 2025 | 6.39 Bn |
| Mar 31, 2025 | 5.40 Bn |
| Dec 31, 2024 | 6.11 Bn |
| Sep 30, 2024 | 6.11 Bn |
| Jun 30, 2024 | 6.31 Bn |
| Mar 31, 2024 | 5.71 Bn |
| Dec 31, 2023 | 5.71 Bn |
| Sep 30, 2023 | 5.72 Bn |
| Jun 30, 2023 | 5.72 Bn |
| Mar 31, 2023 | 5.75 Bn |
| Dec 31, 2022 | 5.72 Bn |
| Sep 30, 2022 | 5.76 Bn |
| Jun 30, 2022 | 6.05 Bn |
| Mar 31, 2022 | 6.02 Bn |
| Dec 31, 2021 | 6.08 Bn |
| Sep 30, 2021 | 6.31 Bn |